ORKA News & Analysis
2 articles
Market Mood
Oruka (ORKA) Insider Sale of $687K Amid 700% Stock Surge
Arjun Agarwal, Senior Vice President of Oruka Therapeutics (ORKA), sold 9,854 shares for approximately $687,000 on June 12-15, 2026. The shares were sold at a weighted average price of $69.72 after experiencing a nearly 700% increase in stock value. Post-transaction, Agarwal's direct holdings decreased by 36.83%, from 26,753 to 16,899 shares. This transaction follows a notable surge in Oruka's stock driven by positive Phase 2 clinical data indicating 63.5% patient clearance with ORKA-001, creating heightened market interest.
Read More
Oruka Therapeutics (ORKA) Price Target Increased to $120 by Leerink
Leerink Partners raised the price target for Oruka Therapeutics, Inc. (ORKA) to $120 from $109 on April 30, maintaining an Outperform rating. On April 27, ORKA announced positive interim results from its EVERLAST-A Phase 2a trial of ORKA-001, revealing a 63.5% response rate at Week 16 for moderate-to-severe plaque psoriasis. The trial's favorable safety profile aligns with the IL-23p19 class of therapies. Long-term data from this study is expected in H2 2026, which may influence investor sentiment toward ORKA and its pipeline of monoclonal antibodies.
Read More